ARS Pharmaceuticals (SPRY) News Today $14.01 -0.10 (-0.71%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Royce & Associates LP Purchases 45,755 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Royce & Associates LP increased its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 7.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 691,455 shares of the company's stock afterNovember 17 at 5:17 AM | marketbeat.comWhat is Leerink Partnrs' Estimate for SPRY FY2027 Earnings?ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Research analysts at Leerink Partnrs lowered their FY2027 earnings per share (EPS) estimates for ARS Pharmaceuticals in a note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst R. Ruiz now expects that the company willNovember 15 at 9:07 AM | marketbeat.comQ4 EPS Estimate for ARS Pharmaceuticals Boosted by AnalystARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Research analysts at William Blair boosted their Q4 2025 earnings per share (EPS) estimates for shares of ARS Pharmaceuticals in a research report issued on Wednesday, November 13th. William Blair analyst L. Hanbury-Brown now forecasts thatNovember 15 at 8:50 AM | marketbeat.comARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ...November 14 at 10:53 AM | finance.yahoo.comARS Pharmaceuticals’ Strong Q3 2024 HighlightsNovember 14 at 10:53 AM | markets.businessinsider.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q3 2024 Earnings Call TranscriptNovember 14 at 10:53 AM | msn.comJames E. Flynn Sells 528,456 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockNovember 14 at 7:42 AM | insidertrades.comGSA Capital Partners LLP Boosts Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)GSA Capital Partners LLP grew its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 67.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 98,900 shares of the company's stock afterNovember 14 at 4:53 AM | marketbeat.comLeerink Partners Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)November 14 at 1:32 AM | markets.businessinsider.comARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 13, 2024 | globenewswire.comARS Pharmaceuticals announces agreement with ALK to commercialize neffyNovember 11, 2024 | markets.businessinsider.comARS Pharmaceuticals (NASDAQ:SPRY) Sets New 52-Week High - Time to Buy?ARS Pharmaceuticals (NASDAQ:SPRY) Sets New 12-Month High - What's Next?November 11, 2024 | marketbeat.comARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024November 11, 2024 | benzinga.comARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United StatesNovember 11, 2024 | globenewswire.comALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)November 9, 2024 | globenewswire.comBrokerages Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) PT at $24.00November 8, 2024 | americanbankingnews.comWilliam Blair Has Positive Estimate for SPRY FY2024 EarningsNovember 8, 2024 | americanbankingnews.comARS Pharmaceuticals (SPRY) Set to Announce Quarterly Earnings on WednesdayARS Pharmaceuticals (NASDAQ:SPRY) will be releasing earnings before the market opens on Wednesday, November 13, Zacks reports.November 7, 2024 | marketbeat.comARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming ConferencesNovember 6, 2024 | finance.yahoo.comWilliam Blair Has Positive Outlook for SPRY FY2024 EarningsARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Equities researchers at William Blair upped their FY2024 earnings per share (EPS) estimates for shares of ARS Pharmaceuticals in a report issued on Monday, November 4th. William Blair analyst L. Hanbury-Brown now anticipates that the companyNovember 6, 2024 | marketbeat.comRaymond James & Associates Buys New Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Raymond James & Associates bought a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 204,783 shares of the company's stock, valued at approximately $2,969,000. RaymNovember 5, 2024 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Buy" by AnalystsShares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have been given a consensus recommendation of "Buy" by the six analysts that are covering the stock, MarketBeat reports. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the cNovember 3, 2024 | marketbeat.comCantor Fitzgerald healthcare analyst holds an analyst/industry conference callNovember 1, 2024 | markets.businessinsider.comAllspring Global Investments Holdings LLC Invests $2.58 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Allspring Global Investments Holdings LLC bought a new position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 178,221 shares of theOctober 30, 2024 | marketbeat.comARS Pharmaceuticals showcases intranasal epinephrine data at ACAAI meetingOctober 25, 2024 | markets.businessinsider.comARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific MeetingOctober 24, 2024 | globenewswire.comARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Down 5% - Should You Sell?ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 5% - Here's What HappenedOctober 23, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Reaches New 12-Month High - What's Next?ARS Pharmaceuticals (NASDAQ:SPRY) Sets New 1-Year High - Time to Buy?October 22, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 4.3% - Should You Buy?ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 4.3% - Still a Buy?October 21, 2024 | marketbeat.comHere's Why We're Not At All Concerned With ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn SituationOctober 19, 2024 | finance.yahoo.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CFO Kathleen D. Scott Sells 12,500 SharesOctober 18, 2024 | insidertrades.comKathleen D. Scott Sells 12,500 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) CFO Kathleen D. Scott sold 12,500 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $16.00, for a total transaction of $200,000.00. Following the sale, the chief financial officer now directly owns 4,949 shares of the company's stock, valued at approximately $79,184. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.October 17, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Hits New 1-Year High - Still a Buy?ARS Pharmaceuticals (NASDAQ:SPRY) Reaches New 52-Week High - Time to Buy?October 16, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Stock Quotes, Forecast and News SummaryOctober 16, 2024 | benzinga.comARS Pharmaceuticals (NASDAQ:SPRY) Stock, Short Interest ReportOctober 15, 2024 | benzinga.comSG Americas Securities LLC Cuts Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)SG Americas Securities LLC lessened its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 47.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 58,304 shares of the company's stock afteOctober 12, 2024 | marketbeat.comSoftware-as-a-service startup Spry Therapeutics secures $15 millionOctober 11, 2024 | msn.comRichard E. Lowenthal Sells 100,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockOctober 11, 2024 | insidertrades.comARS Pharmaceuticals (SPRY) Initiated with a Buy at Cantor FitzgeraldOctober 9, 2024 | markets.businessinsider.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Average Rating of "Buy" from BrokeragesARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) has been assigned an average rating of "Buy" from the six brokerages that are presently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommOctober 9, 2024 | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating for ARS Pharmaceuticals (NASDAQ:SPRY)Cantor Fitzgerald restated an "overweight" rating and set a $30.00 target price on shares of ARS Pharmaceuticals in a research report on Tuesday.October 8, 2024 | marketbeat.comRenaissance Technologies LLC Has $1.06 Million Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Renaissance Technologies LLC grew its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 884.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 124,100 shares of the company's stock afterOctober 7, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Down 2.5%ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Down 2.5%September 24, 2024 | marketbeat.comBank of New York Mellon Corp Purchases 69,394 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Bank of New York Mellon Corp grew its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 99.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 139,285 shares of the company's stock after buySeptember 21, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) PT Raised to $25.00Leerink Partners lifted their target price on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an "outperform" rating in a report on Friday.September 20, 2024 | marketbeat.comEric Karas Sells 10,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockSeptember 20, 2024 | insidertrades.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 10,000 Shares of StockSeptember 19, 2024 | insidertrades.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $140,000.00 in StockARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) insider Eric Karas sold 10,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the transaction, the insider now owns 5,693 shares of the company's stock, valued at $79,702. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.September 19, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Trading 3.1% Higher ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 3.1%September 18, 2024 | marketbeat.com Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address Why buying gold might be a mistake (Ad)Something strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level. If you're interested, check out the recording here while the link's still up. SPRY Media Mentions By Week SPRY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRY News Sentiment▼0.330.56▲Average Medical News Sentiment SPRY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRY Articles This Week▼214▲SPRY Articles Average Week Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BPMC News Today LNTH News Today NUVL News Today RNA News Today ACLX News Today KRYS News Today ADMA News Today TGTX News Today BHVN News Today CRNX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRY) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPRY Stock Alerts